



Clínica
Universidad
de los Andes

CÓMO MEJORAR LOS RESULTADOS A LARGO PLAZO DE BALÓN GÁSTRICO

Dr. Alex Escalona Pérez

Programa de Obesidad y Diabetes
Clínica Universidad de los Andes
Santiago, CHILE



Clínica
Universidad
de los Andes

CÓMO MEJORAR LOS RESULTADOS DEL TRATAMIENTO DE LA OBESIDAD A LARGO PLAZO

Dr. Alex Escalona Pérez

Programa de Obesidad y Diabetes
Clínica Universidad de los Andes
Santiago, CHILE



Clínica
Universidad
de los Andes

The NEW ENGLAND JOURNAL *of* MEDICINE

ORIGINAL ARTICLE

Life Expectancy after Bariatric Surgery in the Swedish Obese Subjects Study


Lena M.S. Carlsson, M.D., Ph.D., Kajsa Sjöholm, Ph.D.,
Peter Jacobson, M.D., Ph.D., Johanna C. Andersson-Assarsson, Ph.D.,
Per-Arne Svensson, Ph.D., Magdalena Taube, Ph.D.,
Björn Carlsson, M.D., Ph.D., and Markku Peltonen, Ph.D.

Carlsson L. et al. *N Engl J Med* 2020; 383: 1535-43

Baja de peso




Clínica
Universidad
de los Andes



Sobrevida a largo plazo



Clínica
Universidad
de los Andes



No. at Risk


Reference	1135	1125	1106	1083	905	0	0
Surgery	2007	1915	1837	1744	1390	580	34
Control	2040	1961	1815	1589	1238	488	26

Trayectoria de peso




Clínica
Universidad
de los Andes

A Roux-en-Y gastric bypass



B Laparoscopic adjustable gastric band



¿Por qué?



Clínica
Universidad
de los Andes

ORIGINAL ARTICLE

Patient Behaviors and Characteristics Related to Weight Regain After Roux-en-Y Gastric Bypass

A Multicenter Prospective Cohort Study

Wendy C. King, PhD,* Steven H. Belle, PhD,*† Amanda S. Hinerman, MPH,* James E. Mitchell, MD,‡
Kristine J. Steffen, PharmD, PhD,§ and Anita P. Courcoulas, MD, MPH¶

Conducta alimentaria y recuperación de peso



Clínica
Universidad
de los Andes

TABLE 4. Associations Between Select Postsurgery Behaviors* and Weight Regain, Measured as Percentage of Maximum Weight Lost

	N	Univariate Models†		Multivariable Model§	
		Beta (95% CI)†	P	Adj. Beta (95% CI)†	P
Weight control practices					
Weighed oneself at least weekly (Ref = no)	1130	−3.61 (−4.68, −2.55)	<0.001	−4.17 (−5.41, −2.93)	<0.001
Eating behaviors					
Number of times ate per day (Ref = 1–2 times)	1128		0.77		
3 or 4 times		0.82 (−1.66, 3.3)			
5 or 6 times		0.61 (−1.89, 3.1)			
7 or more times		0.07 (−2.7, 2.84)			
Number of fast food meals, per 1 time higher per week	1075	0.50 (0.26, 0.75)	<0.001	0.45 (0.19, 0.71)	<0.001
Ate when felt full (Ref = no)	1131	3.46 (1.85, 5.06)	<0.001	2.89 (1.23, 4.55)	<0.001
Ate continuously throughout day (Ref = no)	1126	2.91 (1.87, 3.95)	<0.001	1.61 (0.09, 3.13)	0.04
Disordered eating (Ref = neither)	1118		<0.001		<0.001
Binge eating		9.51 (7.11, 11.92)		8.02 (5.09, 10.96)	
Loss of control eating only		3.39 (2.23, 4.55)		1.60 (−0.06, 3.27)	
Night eating syndrome (Ref = no)	1127	2.44 (0.90, 3.99)	0.002	1.61 (−0.17, 3.40)	0.08
Substance use					
Smoked cigarettes (Ref = no)	1133	−3.53 (−5.58, −1.48)	<0.001	−2.18 (−4.56, 0.20)	0.07
Physical activity					
Leisure MVPA, MET h/wk (Ref = Q1 <1.75)	1133		0.002		
Q2 (1.75 to <8.3)		−0.67 (−1.93, 0.58)			
Q3 (8.3 to <20)		−1.72 (−3.07, −0.38)			
Q4 (≥20)		−2.70 (−4.17, −1.24)			
Leisure/occupational MVPA, MET-h/wk (Ref = Q1 <3.5)	1133		0.002		
Q2 (3.5 to <13.5)		−0.85 (−2.16, 0.45)			
Q3 (13.5 to <47.5)		−1.64 (−3.03, −0.25)			
Q4 (≥47.5)		−2.78 (−4.24, −1.33)			
Sedentary time¶, h/d (Ref = Q1 <2)	1133		<0.001		0.005
Q2 (2 to <3)		1.41 (0.06, 2.77)		0.46 (−1.09, 2.00)	
Q3 (3 to <4.5)		2.27 (0.89, 3.65)		1.58 (−0.005, 3.16)	
Q4 (≥4.5)		3.79 (2.27, 5.32)		2.98 (1.21, 4.75)	
Control variables		NA			
Maximum weight lost, per 1% of baseline weight				0.42 (0.31, 0.52)	<0.001
Weight loss medication (Ref = no)				−0.66 (−2.77, 1.45)	0.54



original article

Mental health and weight regain after bariatric surgery: associations between weight regain and psychiatric and eating-related comorbidities

Maria Francisca F. P. Mauro¹
<https://orcid.org/0000-0003-4702-3915>

Marcelo Papelbaum¹
<https://orcid.org/0000-0001-9237-3741>

Marco Antônio Alves Brasil²
<https://orcid.org/0000-0002-0548-1590>

João Regis Ivar Carneiro²
<https://orcid.org/0000-0002-2085-8130>

Ronir Raggio Luiz³
<https://orcid.org/0000-0002-7784-9905>

João C. Hiluy¹
<https://orcid.org/0000-0002-1199-9193>

José Carlos Appolinario¹
<https://orcid.org/0000-0002-6089-4400>

ABSTRACT

¹ Grupo de Obesidade e Transtornos Alimentares, Instituto de Psiquiatria, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brasil

² Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brasil

³ Instituto de Estudos de Saúde Pública, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brasil

This study was presented at The International Conference on Eating Disorders (ICED), hosted by the Academy for Eating Disorders (AED) in 2020. The conference was hosted online due to the COVID-19 pandemic.

Recuperación de peso



Table 2. Comparison of lifetime and current prevalence of mental disorders in individuals with and without weight regain after Roux-en-Y gastric bypass

Mental Disorders (DSM-IV*)	Lifetime Prevalence		P value	Current Prevalence		P value
	NWR n=40 n (%)	WR n=50 n (%)		NWR n=40 n (%)	WR n=50 n (%)	
Mood disorders						
Major depressive disorder	13 (32.5)	24 (48)	0.13	9 (22.5)	17 (34)	0.23
Dysthymia	0	0	N/A	0	1 (2)	0.36
Bipolar disorder	0	1 (2)	0.36	2 (5)	0	0.11
Anxiety disorders						
Social phobia	7 (17.5)	8 (16)	0.85	7 (17.5)	7 (14)	0.64
Specific phobia	10 (25)	11 (22)	0.73	N/A	N/A	N/A
Generalized anxiety disorder	1 (2.5)	3 (6)	0.42	3 (7.5)	9 (18)	0.14
Panic disorder	2 (5)	6 (12)	0.24	5 (12.5)	5 (10)	0.7
Agoraphobia	2 (5)	8 (16)	0.09	5 (12.5)	9 (18)	0.47
Post-traumatic stress disorder	10 (25)	15 (30)	0.6	7 (17.5)	6 (12)	0.46
Obsessive-compulsive disorder	1 (2.5)	7 (14)	0.05	2 (5)	4 (8)	0.57
Body dysmorphic disorder	2 (5)	3 (6)	0.83	N/A	N/A	N/A
Somatoform disorder	2 (5)	4 (8)	0.57	N/A	N/A	N/A
Substance use disorder						
Alcohol abuse	2 (5)	10 (20)	0.03	4 (10)	6 (12)	0.76
Alcohol dependence	2 (5)	10 (20)	0.03	2 (5)	4 (8)	0.57
Other substance abuse/dependence	5 (12.5)	7 (14)	0.83	1 (2.5)	1 (2)	0.87
Eating disorders*						
Anorexia nervosa	0	1 (2)	0.36	0	0	N/A
Bulimia nervosa	0	6 (12)	0.02	1 (2.5)	0	0.26
Binge-eating disorder	14 (35)	19 (38)	0.76	3 (7.5)	12 (24)	0.03

Recuperación de peso



Table 4. Comparison of general and eating psychopathologies in individuals with and without weight regain after Roux-en-Y gastric bypass

General and Eating Psychopathology*	Groups		P value**	Effect size ***
	NWR n=40 Median (min-max)	WR n=50 Median (min-max)		
Binge Eating Scale	6 (0-26)	11 (0-42)	0.013	0.55
Three-Factor Eating Questionnaire				
Restriction Subscale	13 (4-19)	9.5 (3-19)	0.007	-0.60
Disinhibition Subscale	4 (1-12)	6.5 (2-19)	0.001	0.76
Hunger Subscale	3 (0-12)	4 (1-11)	0.004	0.39
Body Shape Questionnaire	74 (34-192)	89.5 (36-183)	0.06	0.36
Beck Depression Inventory	8.5 (0-49)	9 (0-46)	0.43	0.16
Barratt Impulsiveness Scale				
Total Score	69 (52-80)	71 (51-90)	0.69	0.42
Motor Impulsivity	23 (16-35)	24.5 (17-35)	0.34	0.12
Attentional Impulsivity	21 (14-26)	19.5 (14-28)	0.50	-0.06
Non-Planning Impulsivity	25 (17-34)	27 (16-34)	0.001	0.69

Trastornos alimentarios



Clínica
Universidad
de los Andes

Journal of Human Nutrition and Dietetics



ORIGINAL ARTICLE

Prevalence of Emotional and Binge Eating Among Patients With Obesity Attending a Specialist Weight Management Service for Bariatric Surgery in the United Kingdom


Yousef Alhindi^{1,2,3}  | Guy Holt⁴  | Katy A. Jones⁵ | Najat Khalifa⁶ | Waleed Al-Khyatt⁷ | Iskandar Idris^{1,2,4} 

¹Department of Bariatric Medicine, Royal Derby Hospital Centre, University of Nottingham, Derby, UK | ²National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre, Nottingham, UK | ³Division of Applied Medical Sciences, University of Hail, Hail, Saudi Arabia | ⁴East Midlands Bariatric & Metabolic Institute, Royal Derby Hospital, Derby, UK | ⁵Academic Unit of Mental Health and Clinical Neurosciences, School of Medicine, Institute of Mental Health, University of Nottingham, Nottingham, UK | ⁶Department of Psychiatry, Queen's University, Kingston, Ontario, Canada | ⁷Bariatric & Metabolic Centre of Excellence, Healthpoint Hospital, Abu Dhabi, United Arab Emirates

Trastornos alimentarios



Clínica
Universidad
de los Andes



ORIGINAL ARTICLE

Binge Eating and Weight Loss Outcomes in Overweight and Obese Individuals With Type 2 Diabetes


Results From the Look AHEAD Trial

Amy A. Gorin, PhD; Heather M. Niemeier, PhD; Patricia Hogan, MS; Mace Coday, PhD;
Cralen Davis, MS; Vicki G. DiLillo, PhD; Marci E. Gluck, PhD; Thomas A. Wadden, PhD;
Delia S. West, PhD; Donald Williamson, PhD; Susan Z. Yanovski, MD;
for the Look AHEAD Research Group

Baja de peso



Clínica
Universidad
de los Andes



Gorin A. et al. *Arch Gen Psychiatry* 2008; 65: 1447-1455



Original Article
CLINICAL TRIALS AND INVESTIGATIONS




Binge-Eating Disorder and the Outcome of Bariatric Surgery in a Prospective, Observational Study: Two-Year Results

Ariana M. Chao^{1,2}, Thomas A. Wadden², Lucy F. Faulconbridge², David B. Sarwer³, Victoria L. Webb⁴, Jena A. Shaw², J. Graham Thomas⁵, Christina M. Hopkins², Zayna M. Bakizada², Naji Alamuddin⁶, and Noel N. Williams⁷

Trastorno por atracones



Clínica
Universidad
de los Andes



Trastorno por atracones



Clínica
Universidad
de los Andes

European Eating Disorders Review

WILEY

BRIEF REPORT **OPEN ACCESS**

Binge Eating Behaviour Before and 10 Years Following Metabolic and Bariatric Surgery


Deborah Lynn Reas¹  | Selma Øverland Lie¹ | Tom Mala^{2,3} | Ingela Lundin Kvalem⁴

¹Regional Department for Eating Disorders, Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway | ²Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway | ³Department of Gastrointestinal Surgery and Paediatric Surgery, Oslo University Hospital, Oslo, Norway | ⁴Department of Psychology, Faculty of Social Sciences, University of Oslo, Oslo, Norway

Trastorno por atracones



Clínica
Universidad
de los Andes



Trastorno por atracones



TABLE 2 | Comparison of BE groups (never, remitted, continued, developed) at baseline and 10 years following metabolic and bariatric surgery ($N = 183$).


	Total ($n = 183$)	Never BE ^a ($n = 88$)	Remitted BE ^b ($n = 51$)	Continued BE ^c ($n = 29$)	Developed BE ^d ($n = 15$)	F/x^2	p	n^2/Ω	Bonferroni post hoc
Pre-surgery									
Age	44.8 (9.5)	45.9 (8.9)	46.2 (9.2)	38.3 (9.6)	45.5 (9.6)	4.3	< 0.001	0.064	c < a,b
HADS T1	11.8 (6.7)	10.9 (6.5)	11.6 (6.7)	15.6 (7.1)	10.3 (6.7)	3.26	0.02	0.058	c > a
BMI T1	42.9 (5.4)	42.3 (5.5)	43.7 (5.4)	43.1 (5.4)	43.7 (4.4)	0.84	0.47	0.01	—
Post-surgery									
HADS T2	10.7 (6.91)	8.7 (6.3)	11.2 (7.3)	14.45 (6.9)	13.5 (5.1)	6.19	< 0.001	0.101	c > a
RePeat-Q	1.58 (1.39)	1.19 (1.03)	1.22 (1.23)	2.92 (1.70)	2.47 (1.04)	19.4	< 0.001	0.26	c,d > a,b
CG Avg	1.58 (1.51)	1.19 (1.09)	1.22 (1.45)	2.85 (1.86)	2.64 (1.43)	15.46	< 0.001	0.218	c,d > a,b
RE Avg	1.58 (1.35)	1.21 (1.07)	1.23 (1.09)	3.00 (1.63)	2.29 (0.98)	18.54	< 0.001	0.251	c,d > a,b
BMI T2	32.7 (6.3)	31.9 (6.2)	32.1 (5.4)	35.3 (7.3)	35.4 (6.6)	2.38	0.07	0.040	—
% TWL	23.8 (11.1)	24.3 (11.4)	25.9 (10.7)	19.0 (12.4)	20.2 (9.7)	3.36	0.06	0.057	—
% WR	33.2 (26.0)	31.7 (25.9)	25.9 (24.0)	49.4 (26.3)	37.1 (21.1)	8.40	< 0.001	0.089	c > a,b
% WR $\geq 25\%$	59.2%	54.5%	50%	84%	76.9%	10.5	0.015	0.25	c,d > a,b

Resultado a largo plazo



Clínica
Universidad
de los Andes

Control Ingesta
alimentaria




Control peso
corporal

Evaluación equipo



Clínica
Universidad
de los Andes






Estrategia de tratamiento



Tratamiento TCA

Figure. Eating Disorder Differential Diagnosis, Assessment, and Treatment Considerations



Estrategia de tratamiento





Clínica
Universidad
de los Andes



Terapia combinada



Clínica
Universidad
de los Andes

Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial




Alexander Dimitri Miras*, Belén Pérez-Pevida*, Madhawi Aldhwayan, Anna Kamocka, Emma Rose McGlone, Werd Al-Najim, Harvinder Chahal, Rachel L Batterham, Barbara McGowan, Omar Khan, Veronica Greener, Ahmed R Ahmed, Aviva Petrie, Samantha Scholtz, Stephen R Bloom, Tricia M Tan

Miras AD, et al. *Lancet Diabetes Endocrinol* 2019; 7: 549-59

Diseño



Clínica
Universidad
de los Andes






Figure 2: Effects of liraglutide and placebo over time on HbA_{1c} (A) and bodyweight (B) in participants who completed the trial




Figure 3: Weight loss and glycaemic improvement responses in participants who completed the trial




Research

JAMA Surgery | **Original Investigation**

Safety and Efficacy of Liraglutide, 3.0 mg, Once Daily vs Placebo in Patients With Poor Weight Loss Following Metabolic Surgery The BARI-OPTIMISE Randomized Clinical Trial

Jessica Mok, BMBS, MPhil; Mariam O. Adeleke, PhD; Adrian Brown, PhD; Cormac G. Magee, MBBChir, MA; Chloe Firman, MRes;
Christwishes Makahamadze, MRes; Friedrich C. Jassil, PhD; Parastou Marvasti, PhD; Alisia Carnemolla, PhD; Kalpana Devalia, MBBS, MS; Naim Fakih, MD;
Mohamed Elkalaawy, MRCSEd, MS, MD; Andrea Pucci, MD, PhD; Andrew Jenkinson, MBBS, MS; Marco Adamo, MD; Rumana Z. Omar, PhD;
Rachel L. Batterham, MBBS, PhD; Janine Makaronidis, MBChB, PhD



Complicaciones



Clínica
Universidad
de los Andes

Table 3. Adverse Events (AE)^a in the BARI-OPTIMISE Study Population

Event	Participants who experienced an AE, No. (%)		
	Placebo (n = 35)	Liraglutide (n = 35)	Total (N = 70)
Total	20 (57)	28 (80)	48 (67)
Total AEs, No. ^b	75	37	112
Gastrointestinal events			
Nausea	7 (20)	18 (51)	25 (36)
Diarrhea	2 (6)	2 (6)	4 (6)
Constipation	2 (6)	9 (26)	11 (16)
Vomiting	1 (3)	1 (3)	2 (3)
Abdominal pain	1 (3)	2 (6)	3 (4)
Abdominal bloating	0	1 (3)	1 (1)
Dyspepsia	0	1 (3)	1 (1)
General and administration site events			
Headache	2 (6)	1 (3)	3 (4)
Injection site reaction	3 (9)	2 (6)	5 (7)
Urticaria	0	1 (3)	1 (1)
Fatigue	2 (6)	5 (14)	7 (10)
Insomnia	2 (6)	0	2 (3)
Cardiovascular events			
Dizziness	2 (6)	3 (9)	5 (7)
Palpitations	1 (3)	3 (9)	4 (6)
Infections			
Upper respiratory tract infection	2 (6)	5 (14)	7 (10)
Influenza	2 (6)	3 (9)	5 (7)
Metabolic and nutritional events			
Decreased appetite	3 (9)	11 (31)	14 (20)
Dry mouth	2 (6)	3 (9)	5 (7)
Musculoskeletal events			
Back pain	0	1 (3)	1 (1)
Arthralgia	2 (6)	2 (6)	4 (6)
Serious AEs	0	0	0

Conclusiones

- Control de ingesta alimentaria
- Diagnóstico de condiciones de pérdida de control de ingesta alimentaria
- Educación paciente

Conclusiones

- Intervención oportuna en trastornos alimentarios
- Formación profesionales

Formación profesional



Clínica
Universidad
de los Andes

POSTGRADOS UANDES

Universidad de los Andes

DIPLOMADO EN

Manejo Interdisciplinario de los Trastornos de la Conducta Alimentaria y Obesidad

ESCUELA DE PSICOLOGÍA

Inicio: 2 de mayo de 2025
Modalidad: Semipresencial

Valor: Matrícula 3 UF
Arancel: 47 UF



Clínica
Universidad
de los Andes